Gene-based antiangiogenic applications for corneal neovascularization

Siyin Liu, Vito Romano, Bernhard Steger, Stephen B. Kaye, Kevin J. Hamill, Colin Willoughby

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Corneal avascularity is maintained by angiogenic privilege, an active process involving the production of higher level of angiostatic factors to offset the effect of angiogenic factors. A wide range of pathological insults to the cornea can disrupt this intricate equilibrium and promote angiogenesis and corneal neovascularization with resultant visual impairment. Corneal neovascularization is also a major risk factor for graft failure after keratoplasty. Current treatment options for corneal neovascularization are restricted by limited efficacy, adverse effects, and a short duration of action. The unique anatomical position and relative immune privilege of cornea make it an ideal tissue for gene-based therapies. Gene transfer vectors have been used to deliver or target genes involved in the pathogenesis of corneal neovascularization in animal models. Several proangiogenic and antiangiogenic factors have been targeted and assessed in experimentally induced corneal neovascularization. Antisense oligonucleotides targeting corneal neovascularization have entered human clinical trials and have not required vector delivery systems. The emergence of these RNA-based strategies heralds a new era in the management of corneal neovascularization and ocular therapeutics.
    LanguageEnglish
    Pages193-213
    JournalSurvey of Ophthalmology
    Volume63
    Issue number2
    Early online date15 Nov 2017
    DOIs
    Publication statusE-pub ahead of print - 15 Nov 2017

    Fingerprint

    Corneal Neovascularization
    Genes
    Cornea
    Corneal Transplantation
    Antisense Oligonucleotides
    Angiogenesis Inducing Agents
    Vision Disorders
    Genetic Therapy
    Animal Models
    Clinical Trials
    RNA
    Transplants
    Therapeutics

    Keywords

    • angiogenesis
    • antisense oligonucleotide
    • cornea
    • gene therapy
    • miRNA
    • neovascularization
    • vascular endothelial growth factor

    Cite this

    Liu, Siyin ; Romano, Vito ; Steger, Bernhard ; Kaye, Stephen B. ; Hamill, Kevin J. ; Willoughby, Colin. / Gene-based antiangiogenic applications for corneal neovascularization. In: Survey of Ophthalmology. 2017 ; Vol. 63, No. 2. pp. 193-213.
    @article{ae61895d0a624e5fbeb7a2cfd344281f,
    title = "Gene-based antiangiogenic applications for corneal neovascularization",
    abstract = "Corneal avascularity is maintained by angiogenic privilege, an active process involving the production of higher level of angiostatic factors to offset the effect of angiogenic factors. A wide range of pathological insults to the cornea can disrupt this intricate equilibrium and promote angiogenesis and corneal neovascularization with resultant visual impairment. Corneal neovascularization is also a major risk factor for graft failure after keratoplasty. Current treatment options for corneal neovascularization are restricted by limited efficacy, adverse effects, and a short duration of action. The unique anatomical position and relative immune privilege of cornea make it an ideal tissue for gene-based therapies. Gene transfer vectors have been used to deliver or target genes involved in the pathogenesis of corneal neovascularization in animal models. Several proangiogenic and antiangiogenic factors have been targeted and assessed in experimentally induced corneal neovascularization. Antisense oligonucleotides targeting corneal neovascularization have entered human clinical trials and have not required vector delivery systems. The emergence of these RNA-based strategies heralds a new era in the management of corneal neovascularization and ocular therapeutics.",
    keywords = "angiogenesis, antisense oligonucleotide, cornea, gene therapy, miRNA, neovascularization, vascular endothelial growth factor",
    author = "Siyin Liu and Vito Romano and Bernhard Steger and Kaye, {Stephen B.} and Hamill, {Kevin J.} and Colin Willoughby",
    year = "2017",
    month = "11",
    day = "15",
    doi = "10.1016/j.survophthal.2017.10.006",
    language = "English",
    volume = "63",
    pages = "193--213",
    journal = "Survey of Ophthalmology",
    issn = "0039-6257",
    publisher = "Elsevier",
    number = "2",

    }

    Gene-based antiangiogenic applications for corneal neovascularization. / Liu, Siyin; Romano, Vito; Steger, Bernhard; Kaye, Stephen B.; Hamill, Kevin J.; Willoughby, Colin.

    In: Survey of Ophthalmology, Vol. 63, No. 2, 15.11.2017, p. 193-213.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Gene-based antiangiogenic applications for corneal neovascularization

    AU - Liu, Siyin

    AU - Romano, Vito

    AU - Steger, Bernhard

    AU - Kaye, Stephen B.

    AU - Hamill, Kevin J.

    AU - Willoughby, Colin

    PY - 2017/11/15

    Y1 - 2017/11/15

    N2 - Corneal avascularity is maintained by angiogenic privilege, an active process involving the production of higher level of angiostatic factors to offset the effect of angiogenic factors. A wide range of pathological insults to the cornea can disrupt this intricate equilibrium and promote angiogenesis and corneal neovascularization with resultant visual impairment. Corneal neovascularization is also a major risk factor for graft failure after keratoplasty. Current treatment options for corneal neovascularization are restricted by limited efficacy, adverse effects, and a short duration of action. The unique anatomical position and relative immune privilege of cornea make it an ideal tissue for gene-based therapies. Gene transfer vectors have been used to deliver or target genes involved in the pathogenesis of corneal neovascularization in animal models. Several proangiogenic and antiangiogenic factors have been targeted and assessed in experimentally induced corneal neovascularization. Antisense oligonucleotides targeting corneal neovascularization have entered human clinical trials and have not required vector delivery systems. The emergence of these RNA-based strategies heralds a new era in the management of corneal neovascularization and ocular therapeutics.

    AB - Corneal avascularity is maintained by angiogenic privilege, an active process involving the production of higher level of angiostatic factors to offset the effect of angiogenic factors. A wide range of pathological insults to the cornea can disrupt this intricate equilibrium and promote angiogenesis and corneal neovascularization with resultant visual impairment. Corneal neovascularization is also a major risk factor for graft failure after keratoplasty. Current treatment options for corneal neovascularization are restricted by limited efficacy, adverse effects, and a short duration of action. The unique anatomical position and relative immune privilege of cornea make it an ideal tissue for gene-based therapies. Gene transfer vectors have been used to deliver or target genes involved in the pathogenesis of corneal neovascularization in animal models. Several proangiogenic and antiangiogenic factors have been targeted and assessed in experimentally induced corneal neovascularization. Antisense oligonucleotides targeting corneal neovascularization have entered human clinical trials and have not required vector delivery systems. The emergence of these RNA-based strategies heralds a new era in the management of corneal neovascularization and ocular therapeutics.

    KW - angiogenesis

    KW - antisense oligonucleotide

    KW - cornea

    KW - gene therapy

    KW - miRNA

    KW - neovascularization

    KW - vascular endothelial growth factor

    U2 - 10.1016/j.survophthal.2017.10.006

    DO - 10.1016/j.survophthal.2017.10.006

    M3 - Article

    VL - 63

    SP - 193

    EP - 213

    JO - Survey of Ophthalmology

    T2 - Survey of Ophthalmology

    JF - Survey of Ophthalmology

    SN - 0039-6257

    IS - 2

    ER -